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Abstract
Purpose of Review—This review will examine the recent advances in our understanding of the
genetic and molecular events that shape this cancer, and overview the emerging targeted therapies
that have altered the landscape for renal cell carcinoma (RCC) patients.
• The incidence of RCC continues to rise, making it the 7th and 8th most common cancer
among men and women in the U.S., respectively.
• VHL loss is an important factor in the development of clear cell RCC, however:
Loss of VHL can result in tumors which express both HIF1 and HIF2, or HIF2 alone,
correlating with distinct pathway activities
Invasive tumors demonstrating loss of VHL consistently demonstrate additional
genetic changes, which appear to be essential for tumor progression.
• Targeted therapies have demonstrated improvements in overall survival
• New ways to radiographically measure the tumor response to these treatments may provide
additional information about a drug’s activity in an individual patient.
• VEGF receptor TKIs are still being investigated in the adjuvant setting.
Summary—The field of RCC biology continues to rapidly change. As new targeted strategies to
control this cancer evolve, so do both the clinical strategies, and the strategies to measure response
and predict outcome.
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Introduction
Renal cell carcinoma continues to rise in incidence and garner increased attention as new
biological and therapeutic details emerge for this once obscure cancer. The biology of RCC
relevant to clear cell histology disease still hinges on VHL mutation as an important initiating
event in most tumors. Similarly, the landscape for RCC treatment has changed dramatically in
recent years, with the addition in 2009 of three new FDA-approved agents for RCC.
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Epidemiology and factors contributing to renal cell carcinoma
Renal cell carcinoma continues to represent an increasing proportion of the cancer landscape.
This year 58,000 new cases of RCC are expected in the U.S., reflecting a continued increase
in incidence [1]. This steady rise, continuing over the past 20 years, to a large extent reflects
an increase in the radiographic identification of incidental masses. However, RCC mortality
has not declined in that time frame, implying that the increase in diagnoses is not solely due
to early detection. As a result of this steady increase, and the declines seen in other cancers,
RCC has risen to become the 7th most common cancer in men and the 8th most common cancer
in women in the U.S. [1] (Figure 1). In all, one in 70 individuals will be diagnosed with this
cancer.
Advances in genetics and biology of renal cell carcinoma
Recent advances in the biology of RCC include increased demonstration of VHL-associated
molecular features. A recent study by Gordan, et al, demonstrated three subgroups of clear cell
tumors: those with wild type VHL (which lacked widespread expression of HIF1 or HIF2),
and those harboring VHL mutation or hypermethylation, which were further subdivided into
HIF1/HIF2-expressing and HIF2-expressing tumors. Although the impact on tumor behavior
is uncertain, the effect of these molecular phenotypes on tumor gene expression and pathway
activation was remarkable, with VHL mutant/HIF2 tumors in particular demonstrating
activation of myc signaling and defects in normal cell cycle regulation [2], Further, a gene
expression and genomic analysis of sporadic and VHL disease-associated renal masses found
a high degree of similarity between the VHL disease tumors and a homogenous subgroup of
the sporadic tumors. This analysis, which demonstrated 3p chromosomal losses in virtually
every tumor, also importantly demonstrated a consistency of losses and gains of genetic
material, which may be valuable for future therapeutic development [3]. Finally, an analysis
of cytogenetics demonstrated chromosomal aberrations with a high degree of consistency with
these observations, which were correlated with patients’ survival. Losses at chromosome 3p
were largely associated with favorable outcome as has been suggested previously, whereas
losses in regions of chromosomes 4q, 9p, and 14q were particularly associated with poor risk
[4].
Looking to specific genes involved in RCC, recent mouse models demonstrated the relevance
of common genes associated with heritable renal cancer syndromes across animal species. The
folliculin gene has been linked to the Birt-Hogg-Dube syndrome, predisposing to chromophobe
RCC and oncocytoma [5]. In work by Hartman, et al. a mouse model of folliculin loss
demonstrated the spontaneous development of cysts and tumors resembling oncocytoma [6]
[7]. This animal model represents the first legitimate genetically engineered mouse model of
any of the RCCs, and will hopefully pave the way for other model systems, which can be useful
for guiding the development of therapeutic and diagnostic strategies. In a model of VHL
disease, our group engineered a VHL gene missense mutation which displayed a predisposition
for renal tumor formation following chemical mutagenesis with a potent alkylating agent
(Figure 2) [8]. This model of VHL-induced renal tumorigenesis suggests the essential need for
additional genetic events to promote renal tumorigenesis, similar to the observations in patient
samples that demonstrate significant (and predictable) genetic events coinciding with VHL
loss.
Detection of renal cell carcinoma
Computed tomography (CT) has been a mainstay of renal mass detection for many years. With
the increased resolution of scans, particularly with the current generation of contrast agents,
the potential to use densitometry and three-dimensional measurements to evaluate the kidney
has led to several new and important advances. First, computer assisted radiology tools can
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permit highly consistent measurements of kidney tumor 3D geometry and enhancement. Such
a strategy demonstrated a significant capability to distinguish between cysts and small renal
masses in patients with hereditary renal carcinoma syndromes [9], and could be particularly
valuable to correctly assign the increasing number of incidentally detected small renal lesions
or provide accurate surveillance of such masses that have low metastatic potential.
A second application of this kind of re-analysis of conventional CT imaging examines
intratumoral density as a measure of disease response to therapy. Similar strategies were
employed to analyze conventional contrast-enhanced CT images for changes in tumor density,
demonstrating correlation with both uni-dimensional tumor response and progression-free
survival for patients treated with VEGF pathway-targeted agents [10] [11]. An example of this
densitometric change in a primary tumor is demonstrated in Figure 3. Further standardization
of the method for quantifying these measurements is required, but ultimately such three-
dimensional measures of disease response may represent a more accurate quantification of
response to therapeutics.
Management of localized disease
The management of localized disease, particularly for small renal masses, has continued to
evolve. With the advent of robotic laparoscopic surgery for bladder and prostate cancers, it is
not surprising that this is also being extended to localized renal masses. This approach is gaining
popularity; with good oncologic outcomes expected for most patients with small renal masses,
the selection of a particular treatment approach becomes a matter of considering co-morbidities
and other factors. The National Cancer Institute has applied the robotic approach to partial
laparoscopic nephrectomy for multiple tumors, largely focused on patients with heritable renal
cancer syndromes, and has found that this approach is promising and worthy of further
investigation [12]. Further, this technique has provided the opportunity to dispense with
clamping the renal hilum, a particularly important consideration for patients predisposed to
developing renal carcinoma, who can anticipate repeated interventions over their lifetime.
As these surgical approaches have evolved, so have ablative therapies, as well as the
appreciation that many small lesions may have low metastatic potential. This topic,
complicated by multiple modalities of ablative therapy and the lack of definitive radiographic
strategies to discern dangerous small lesions from indolent masses, has been thoroughly
reviewed [13]. Ultimately, comparative studies are required to demonstrate the assumed
equivalence of these strategies.
Adjunctive therapy
Adjuvant and neoadjuvant treatments for RCC represent an important opportunity for reducing
the risk of disease recurrence, and potentially expanding the group of patients cured of this
cancer.
Adjuvant therapy
Historically, adjuvant trials of cytokine-based therapies have been disappointing,
demonstrating lack of improvement over surgical treatment alone, or in some cases trends
toward shortened survival [14,15]. Recent efforts to implement novel strategies of immune
system modulation have been the first to demonstrate a potential for improved outcome. In the
10-year survival analysis of a study of autologous tumor lysate vaccine adjuvant therapy, a
trend was demonstrated toward increased survival in all patients, with a statistically significant
improvement observed for patients with T3 tumors. In multivariate analysis, the T3 tumor
subgroup continued to demonstrate improved survival, HR=1.67, p=0.011 [16]. In a move
toward advancing targeted anti-angiogenesis therapy to the adjuvant setting, a small study was
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performed at MD Anderson Cancer Center exploring the use of adjuvant thalidomide. Forty-
six patients were enrolled to a randomized study of observation vs. thalidomide 300mg daily
for 24 months. Unfortunately, the two- and three-year cancer-specific survivals were not
improved with treatment, and the thalidomide-treated patients actually had poorer survival at
two and three years (47.8% vs 69.3% and 28.7% vs 69.3%, respectively; P = .022) [17].
Much attention is being focused on several ongoing studies testing the adjuvant use of VEGF-
receptor tyrosine kinase inhibitor (TKI) therapy. Despite the failure of thalidomide to
demonstrate activity in this venue, evidence from the metastatic disease setting suggests that
the VEGF-receptor TKIs are much more potent against RCC. Multiple studies are ongoing and
anticipated to complete enrollment in the coming year. These studies include: the ASSURE
study, randomizing patients with completely resected clear cell tumor larger than 4cm to 1 year
of sunitinib, sorafenib, or placebo, at conventional doses; the SORCE study, randomizing
completely resected RCC tumors (any histology) in Europe that are intermediate or high risk
according to the Leibovich score [18] to one year or three years of sorafenib at standard dose,
or placebo; and finally, a smaller study comparing standard dose sunitinib to placebo
(randomized 2:1) (Table 1). While these studies will take time to fully mature, they will provide
immediate demonstration of the acute and longer term side effects of prolonged therapy in
otherwise quite healthy individuals, and ultimately represent the most promising avenue of
potential risk reduction for patients facing high risk for recurrence. As exciting as these
strategies are, a complete analysis of adverse events and risk reduction is lacking, and such
treatments at this time should be reserved exclusively for clinical trials.
Neoadjuvant
With drugs that can induce initial tumor shrinkage, it has become relevant to determine whether
implementation of pre-operative treatment can impact primary tumors to reduce tumor bulk
prior to surgery. Such an intervention may permit less invasive surgical approaches, or render
“unresectable” disease “resectable,” or provide an opportunity to gain control of systemic
disease prior to removal of the primary mass. Several studies have begun to evaluate these
approaches. The use of bevacizumab was investigated in the pre-operative setting for patients
undergoing cytoreductive nephrectomy. This study of 50 patients demonstrated responses in
the primary tumor, but led to wound dehiscence in three patients, likely due to the long half-
life of the antibody [19]. Retrospective studies of a variety of VEGF pathway targeted agents
with widely varied durations of therapy prior to surgery demonstrated the approach was feasible
[20,21]. Sunitinib treatment until best response was employed in 19 patients with inoperable
tumors, with four proceeding to nephrectomy without encountering any unexpected surgical
morbidity [22]. A prospective study using sorafenib in a 4–8 week window prior to surgery
and continuing to within 48 hours of surgery defined the safety risks, which were minimal, and
demonstrated a response in the primary tumor similar to that observed for systemic disease
[23]. This study also highlighted the necessity for pretreatment biopsy, as two of the 30 patients
on the study were found at nephrectomy to have non-renal cell primary tumors. Overall, these
approaches are rational to consider for selected patients, appear to pose minimal risk for decline
in performance status for surgery, and can achieve responses in primary tumors. Further
investigation is necessary to determine the patient groups most likely to benefit from
neoadjuvant therapy, and whether risk for disease recurrence can be reduced. In addition, the
optimal duration of treatment prior to surgery needs to be defined.
Recent advances in systemic therapy for metastatic disease
VEGF receptor TKIs and drugs that inhibit mTOR signaling have become the mainstay for the
management of metastatic disease based on improved progression-free survival or/and overall
survival outcomes.
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Sunitinib has emerged as the current standard of care for first line therapy for patients with
good or intermediate risk clear cell RCC. However, sorafenib remains an appropriate first line
choice for selected patients, and recently pazopanib has received FDA approval, adding a third
agent in this crowded field. Now, with prolonged experience and exposure to these drugs, new
questions are emerging with regard to late side effects, disease control issues, and causes of
disease resistance. These issues are being investigated with new insights into the etiology and
mechanism of cardiac toxicity related to sunitinib. It is apparent that patients with pre-existing
hypertension and coronary heart disease compose the group at greatest risk for encountering
these effects [24]. Preclinical analysis suggests that sunitinib may be directly toxic to cardiac
myocytes [25]. Moreover, the lasting effects of sunitinib exposure to endothelial and other
tissues remain largely unknown. It is concerning that administration of high dose IL-2 after
sunitinib failure has demonstrated a high incidence of severe cardiac toxicity, suggesting that
damage may remain for some time after TKI therapy is discontinued [26]. Ultimately, what is
becoming clear is the need to aggressively manage toxicities in order to maintain patients on
optimally dosed therapy and avoid detrimental long-term complications [27,28].
Effective disease control has been inferred from significant improvements in progression-free
survival. Now with more substantial follow up, the front-line study of sunitinib vs. interferon
has demonstrated an overall survival benefit (26.4 v 21.8 months, p = 0.51), even in the setting
of 65% of the interferon patients crossing over to receive sunitinib or another VEGF pathway
targeted agent [29]. This survival benefit is modest, but suggests that additional consideration
to questions such as when to initiate therapy (early vs late) may be important to investigate
formally.
How RCCs initially responding to treatment with VEGF TKI therapy eventually develop
resistance to these drugs is also garnering considerable interest. Understanding resistance
mechanisms may allow strategies to delay or overcome resistance. Kinase mutations that cause
resistance to drugs like imatinib do not appear to play a role here. Ongoing studies suggest
angiogenic escape mechanisms may contribute to this process [30]. One intriguing experiment
examining xenografts resistant to sorafenib demonstrates that they regain sensitivity when
transplanted into new hosts [31]. How adapted strategies of drug delivery, schedule, or
combination therapy may eliminate this problem is of utmost concern.
mTOR pathway inhibition
An alternate mechanism of targeted therapy for RCC is the inhibition of mTOR signaling via
disruption of the mTORC1 complex. While the activities of mTOR inhibitors (temsirolimus
and everolimus being the only rapalogues approved for RCC) on cancer cells remains an active
area of investigation, we have learned how to strategically place them in the treatment of RCC
patients. In the front line setting, temsirolimus has continued to be the mainstay for patients
with poor risk disease, given the improvement in overall survival and it's good side effect
profile [32]. This year everolimus was approved based on a study that evaluated this drug after
disease progression on one or both VEGF receptor TKIs [33,34]. Patients demonstrated a
doubling of progression-free survival. Thus, the mTOR pathway provides an ideal scenario for
switching drug classes upon disease progression. Ongoing and future studies are actively
exploring the appropriateness of switching drug classes upon disease progression.
Combination strategies
Efforts to enhance efficacy by combining two or more agents has employed two basic
approaches. “Vertical inhibition” describes combinations of therapies that target factors
working in a linear signaling pathway, as opposed to “Lateral inhibition” which implies
inhibiting targets from non-overlapping pathways [35]. The first example of vertical inhibition
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demonstrated that maximally inhibiting the VEGF signaling pathway with bevacizumab
inhibition of soluble VEGF ligand in combination with inhibition of VEGF receptor signaling
with sorafenib could increase response rate, but at the expense of increased toxicity [36].
Whether an improved response rate translates into improvement in progression-free or overall
survival is an active area of investigation.
Lateral inhibition takes the form of combinations of VEGF targeted agents and mTOR
inhibitors. The combination of sunitinib with temsirolimus unfortunately demonstrated
unacceptable toxicity, particularly a high incidence of microangiopathic hemolytic anemia
[37]. Bevacizumab has been amenable to combinations in many settings, and tolerable doses
have been identified for combination with temsirolimus; an ongoing study is evaluating the
bevacizumab/temsirolimus combination vs. bevacizumab/interferon. Other ongoing
combinations of RCC targeted therapies with chemotherapy, cytokine therapy, or novel agents
remain the realm of clinical trials. These studies ultimately will need to address competing
values of tumor response vs. tumor control vs. prolongation of survival vs. drug related side
effects in the context of combination as opposed to sequential single agent therapies.
Conclusion
The field of renal cell carcinoma biology and management continues to evolve. The biology
relevant to clear cell histology disease continues to hinge on VHL mutation as an important
initiating event in most tumors. However, important nuances have emerged. First, the disease
pathophysiology may hinge more on the end effect of VHL inactivation (deregulation of both
HIF1 and HIF2 or HIF2 alone). Thus, where VHL has failed to emerge as an important
biomarker, the end effect on the HIF transcription factor profile may dictate tumor biology
critical to therapeutic response or overall disease behavior. Additionally, work from human
tumor samples and mouse models suggest that not only secondary events occur, but are
necessary for tumor progression. Further studies of human tumor genetic loci and signal
transduction pathways affected in this cancer which supplement VHL mutation will be essential
to generating realistic animal models, and may be effective for designing and utilizing targeted
therapy for expanded benefit in renal cell carcinoma.
The landscape for renal cell carcinoma treatment has changed dramatically in recent years,
with the addition of three new FDA-approved agents this year. This brings our arsenal to seven
drugs: interleukin-2, the VEGF receptor TKI’s sunitinib, sorafenib, and pazopanib, the VEGF
neutralizing antibody bevacizumab in combination with interferon, and the mTOR inhibitors
temsirolimus and everolimus. As new targeted strategies to control renal cell carcinoma evolve,
so do the strategies to measure response and predict outcome.
Finally, how best to tailor the sequential use of these agents remains an object of intense
scrutiny, although regular updates of the NCCN guidelines (with two updates in 2009) endeavor
to provide guidance as new therapeutic options emerge [38]. The use of targeted therapies in
combination, or as adjuncts to nephrectomy, are interesting but limited to clinical studies with
the exception of highly unique clinical scenarios.
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New cases of renal cell carcinoma make up 5% of cancers in males, 3% in females. Adapted
with permission from [1].
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Examples of renal neoplasms arising in the kidney of genetically engineered mice following
treatment with ethyl nitrosourea. Adapted with permission from [8].
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Radiographic Responses to Neoadjuvant Sorafenib Therapy. A. Patient A with a large right-
sided RCC prior to therapy. B. Patient A following 59 days of sorafenib therapy with significant
intratumoral necrosis. C. Patient B with a prominent left-sided RCC, pretreatment. D. Patient
B after 37 days of sorafenib with downstaging from T2 to T1.
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Table 1














SORCE Leibovich score 3–11
Any histology





S-TRAC UISS high risk
>50% clear cell
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